利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

177 条记录 (耗时 0.048 秒)

    Method for treating cachexia with retinoid ligands
    6.
    发明申请
    Method for treating cachexia with retinoid ligands 审中-公开
    用维甲酸配体治疗恶病质的方法

    公开(公告)号：US20070185055A1

    公开(公告)日：2007-08-09

    申请号：US11348520

    申请日：2006-02-06

    申请人： Guang Liang Jiang ,  Yang-Dar Yuan ,  Roshantha A. Chandraratna

    发明人： Guang Liang Jiang ,  Yang-Dar Yuan ,  Roshantha A. Chandraratna

    IPC分类号： A61K31/695 ,  A61K31/382 ,  A61K31/353 ,  A61K31/192 ,  A61K31/215

    CPC分类号： A61K31/192 ,  A61K31/215 ,  A61K31/353 ,  A61K31/382 ,  A61K31/695

    摘要： The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.

    摘要翻译： 本发明涉及治疗需要治疗的受试者的恶病质的方法。 更具体地，本发明涉及作用于类视黄醇X受体（RXR）的类视黄醇化合物用于治疗需要治疗的受试者的恶病质的用途。 恶病质与主要疾病，病症或障碍的并发症相关联。 原发性疾病，病症和障碍包括但不限于癌症，艾滋病，肝硬化，糖尿病，慢性肾衰竭，慢性阻塞性肺病，慢性心力衰竭，免疫系统疾病（例如类风湿性关节炎和系统性红斑狼疮） ，结核病，囊性纤维化，胃肠道疾病（例如肠易激综合征和炎性肠病），帕金森病，神经性厌食症，痴呆，重性抑郁症，老年病症和肌肉减少症。

    Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
    7.
    发明授权
    Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals 失效
    用于降低糖尿病哺乳动物血清葡萄糖和甘油三酯水平的组合物和方法

    公开(公告)号：US07019034B2

    公开(公告)日：2006-03-28

    申请号：US10738808

    申请日：2003-12-17

    申请人： Yang-Dar Yuan ,  Richard L. Beard ,  Roshantha A. Chandraratna

    发明人： Yang-Dar Yuan ,  Richard L. Beard ,  Roshantha A. Chandraratna

    IPC分类号： C07C69/76 ,  A61K31/19

    CPC分类号： C07C69/734 ,  C07C59/72 ,  C07C2602/10

    摘要： Diabetic mammals are treated with compounds that are significantly more efficacious as agonists of RXRβ retinoid receptors than as agonists of RXRα or RXRγ retinoid receptors. The treatment reduces serum glucose and triglyceride levels of the mammals without the undesirable side effects of reducing serum thyroxine levels and a transient increase in serum triglyceride levels Compounds suitable for use in the methods of treatments of the present invention are selected by testing and identifying compounds of selective or specific efficacy as agonists of RXRβ retinoid receptors in preference over RXRα and/or RXRγ retinoid receptors. Novel compounds used in the methods of the invention have Formula 1 where the variables are defined as disclosed in the specification.

    摘要翻译： 糖尿病哺乳动物用作为RXRα2类视黄醇受体的激动剂比作为RXRα或RXRαγ类视黄醇受体的激动剂显着更有效的化合物治疗 。 该治疗降低了哺乳动物的血清葡萄糖和甘油三酯水平，而没有不利的降低血清甲状腺素水平的副作用和血清甘油三酯水平的瞬时增加。适用于本发明治疗方法的化合物通过测试和鉴定化合物 选择性或特异性的功效优于RXRα和/或RXRαγ类视黄醇受体的RXRβ类视黄醇受体的激动剂。 用于本发明方法的新化合物具有式1，其中变量如说明书中所公开的那样定义。

    Methods for treating chemotherapy and radiation therapy side effects
    8.
    发明申请
    Methods for treating chemotherapy and radiation therapy side effects 有权
    治疗化疗和放射治疗副作用的方法

    公开(公告)号：US20090176862A1

    公开(公告)日：2009-07-09

    申请号：US12291994

    申请日：2008-11-13

    申请人： Roshantha A. Chandraratna ,  Yang-Dar Yuan

    发明人： Roshantha A. Chandraratna ,  Yang-Dar Yuan

    IPC分类号： A61K31/382 ,  A61K31/165

    CPC分类号： A61K31/015 ,  A61K31/167 ,  A61K31/192 ,  A61K31/202 ,  A61K31/353 ,  A61K31/382 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/47

    摘要： A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR inverse agonist which binds to receptors of the RARα, RARβ and RARγ subtypes is disclosed. Such side effects include chemoradiotherapy-induced alopecia, chemoradiotherapy-induced thrombocytopenia, chemoradiotherapy-induced leucopenia and chemoradiotherapy-induced neutropenia.

    摘要翻译： 一种用于在接受化疗和/或放射治疗的哺乳动物中治疗化疗或放射治疗副作用的方法，所述方法包括向哺乳动物施用治疗有效量的RAR拮抗剂或RAR反向激动剂的步骤，RAR拮抗剂或RAR反向激动剂结合 披露了RARalpha，RARbeta和RARgamma亚型。 这种副作用包括放化疗诱导的脱发，放化疗诱导的血小板减少症，放化疗诱导的白细胞减少和放化疗引起的中性粒细胞减少。